Monday, August 1, 2016

BRIEF-Seattle Genetics-randomized phase 3 clinical trial with ADCETRIS meets primary endpoint

* Takeda and Seattle Genetics announce positive data from

phase 3 Alcanza clinical trial of ADCETRIS (Brentuximab

Vedotin) for CD30-expressing cutaneous T-Cell Lymphoma

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)